ASND
Neutral signalScored 2026-09-05 Drivers: fundamentals. Moteurs : fondamentaux.
Research, not advice.
À propos
Ascendis Pharma A/S
- Nom
- Ascendis Pharma A/S
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $15.2B
- Employés
- 1,189
- PDG
- Jan Moller Mikkelsen
- Site web
- https://ascendispharma.com
- Marché
- BMRNCORTINSMMBXNBIXRARE
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 2 000 titres (~491 700,00 $ US) VENTE TOTALE: 236 titres (~62 334,59 $ US)
- Insiders
- HOLTUG LARSBIENAIME JEAN JACQUES
- Total bought
-
$491,700
Avg buy (VWAP, 90d window) $246.91 vs last close —
- Total sold
-
$872,905
Avg sell (VWAP, 90d window) $269.75 vs last close —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-02
- Last synced
-
2026-09-08 09:54:45
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-08 | Bodenhoff Mads | Sell · S | 3,000 | $270.19 | $810,570 | Form 4 |
| 2026-09-02 | HOLTUG LARS | Sell · S | 236 | $264.13 | $62,335 | Form 4 |
| 2026-08-14 | BIENAIME JEAN JACQUES | Buy · P | 900 | $246.91 | $222,219 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2018-10-05 | Gary James Palmer | Sale (Full) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-09-05 Drivers: fundamentals. Moteurs : fondamentaux.
ASND presents a meaningful event-driven opportunity: the BioMarin binding term sheet resolving all YUVIWEL patent disputes is a high-quality catalyst, reinforced by credible insider cluster buying (~$429k) from senior…
The first sentence of the analysis written for ASND on 2026-09-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Sale value outweighs purchases
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Unavailable or mixed. No stored price series
- Financial indicators Pulls against a bullish reading. Current ratio 1.04 · operating margin -19%
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 85.1% | 87.8% | 83.4% | 76.3% | 54.7% | |
| Ebit Margin | -18.3% | -84.6% | -161.2% | -1069.2% | -4886.0% | |
| Ebitda Margin | -15.9% | -79.8% | -154.2% | -1034.1% | -4688.1% | |
| Operating Profit Margin | -18.9% | -76.7% | -170.8% | -1097.9% | -5808.6% | |
| Pretax Profit Margin | -29.5% | -102.6% | -177.8% | -1129.1% | -4936.3% | |
| Continuous Operations Profit Margin | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% | |
| Net Profit Margin | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% | |
| Bottom Line Profit Margin | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% | |
| Current Ratio | 1.037 | 1.169 | 0.954 | 1.288 | 8.030 | |
| Quick Ratio | 0.755 | 0.843 | 0.670 | 1.106 | 7.279 | |
| Solvency Ratio | -0.138 | -0.280 | -0.476 | -0.685 | -1.829 | |
| Cash Ratio | 0.576 | 0.616 | 0.532 | 0.621 | 4.447 | |
| Price To Earnings Ratio | -50.135 | -20.360 | -13.327 | -10.967 | -16.901 | |
| Price To Earnings Growth Ratio | 1.125 | 0.862 | 0.749 | -0.226 | 1.093 | |
| Forward Price To Earnings Growth Ratio | 1.125 | 0.862 | 0.749 | -0.226 | 1.093 | |
| Price To Earnings Diluted Ratio | -50.135 | -20.360 | -13.327 | -10.967 | -16.901 | |
| Price To Earnings Diluted Growth Ratio | 1.125 | 0.862 | 0.749 | -0.226 | 1.093 | |
| Price To Book Ratio | -67.585 | -72.811 | -44.021 | 24.285 | 7.333 | |
| Price To Sales Ratio | 15.902 | 21.165 | 24.047 | 124.973 | 833.095 | |
| Price To Free Cash Flow Ratio | 252.168 | -25.019 | -13.652 | -12.535 | -14.664 | |
| Price To Operating Cash Flow Ratio | 212.469 | -25.136 | -13.723 | -12.902 | -15.515 | |
| Debt To Assets Ratio | 0.669 | 0.726 | 0.900 | 0.567 | 0.193 | |
| Debt To Equity Ratio | -5.354 | -8.104 | -5.100 | 2.345 | 0.238 | |
| Debt To Capital Ratio | 1.230 | 1.141 | 1.244 | 0.701 | 0.192 | |
| Long Term Debt To Capital Ratio | 1.732 | 1.408 | 2.885 | 0.266 | 0.100 | |
| Financial Leverage Ratio | -8.000 | -11.158 | -5.666 | 4.138 | 1.228 | |
| Working Capital Turnover Ratio | 7.184 | 6.101 | 3.085 | 0.112 | 0.011 | |
| Operating Cash Flow Ratio | 0.048 | -0.337 | -0.635 | -0.692 | -4.162 | |
| Operating Cash Flow Sales Ratio | 0.075 | -0.842 | -1.752 | -9.687 | -53.696 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.843 | 1.005 | 1.005 | 1.029 | 1.058 | |
| Debt Service Coverage Ratio | -0.221 | -0.529 | -0.899 | -1.205 | -33.401 | |
| Interest Coverage Ratio | -1.690 | -4.256 | -10.338 | -18.311 | -115.518 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.106 | -0.623 | -1.109 | -1.200 | -59.707 | |
| Operating Cash Flow Coverage Ratio | 0.059 | -0.357 | -0.629 | -0.803 | -1.990 | |
| Capital Expenditure Coverage Ratio | 6.352 | -214.574 | -191.385 | -34.212 | -17.234 | |
| Dividend Paid And Capex Coverage Ratio | 6.352 | -214.574 | -191.385 | -34.212 | -17.234 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -102.509 | -27.562 | -16.452 | -12.412 | -17.122 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 85.1% | ▼-2.8% | ▲7.6% |
| Ebit Margin | -18.3% | ▲66.3% | ▲1225.5% |
| Ebitda Margin | -15.9% | ▲63.9% | ▲1178.5% |
| Operating Profit Margin | -18.9% | ▲57.7% | ▲1415.6% |
| Pretax Profit Margin | -29.5% | ▲73.1% | ▲1245.5% |
| Continuous Operations Profit Margin | -31.7% | ▲72.3% | ▲1245.8% |
| Net Profit Margin | -31.7% | ▲72.3% | ▲1245.8% |
| Bottom Line Profit Margin | -31.7% | ▲72.3% | ▲1245.8% |
| Current Ratio | 1.037 | ▼-0.132 | ▼-1.459 |
| Quick Ratio | 0.755 | ▼-0.088 | ▼-1.376 |
| Solvency Ratio | -0.138 | ▲0.142 | ▲0.544 |
| Cash Ratio | 0.576 | ▼-0.040 | ▼-0.782 |
| Price To Earnings Ratio | -50.135 | ▼-29.775 | ▼-27.797 |
| Price To Earnings Growth Ratio | 1.125 | ▲0.263 | ▲0.404 |
| Forward Price To Earnings Growth Ratio | 1.125 | ▲0.263 | ▲0.404 |
| Price To Earnings Diluted Ratio | -50.135 | ▼-29.775 | ▼-27.797 |
| Price To Earnings Diluted Growth Ratio | 1.125 | ▲0.263 | ▲0.404 |
| Price To Book Ratio | -67.585 | ▲5.226 | ▼-37.025 |
| Price To Sales Ratio | 15.902 | ▼-5.263 | ▼-187.935 |
| Price To Free Cash Flow Ratio | 252.168 | ▲277.188 | ▲214.909 |
| Price To Operating Cash Flow Ratio | 212.469 | ▲237.605 | ▲183.431 |
| Debt To Assets Ratio | 0.669 | ▼-0.057 | ▲0.058 |
| Debt To Equity Ratio | -5.354 | ▲2.749 | ▼-2.159 |
| Debt To Capital Ratio | 1.230 | ▲0.089 | ▲0.328 |
| Long Term Debt To Capital Ratio | 1.732 | ▲0.325 | ▲0.454 |
| Financial Leverage Ratio | -8.000 | ▲3.158 | ▼-4.108 |
| Working Capital Turnover Ratio | 7.184 | ▲1.083 | ▲3.885 |
| Operating Cash Flow Ratio | 0.048 | ▲0.386 | ▲1.204 |
| Operating Cash Flow Sales Ratio | 0.075 | ▲0.917 | ▲13.255 |
| Free Cash Flow Operating Cash Flow Ratio | 0.843 | ▼-0.162 | ▼-0.145 |
| Debt Service Coverage Ratio | -0.221 | ▲0.308 | ▲7.030 |
| Interest Coverage Ratio | -1.690 | ▲2.566 | ▲28.333 |
| Short Term Operating Cash Flow Coverage Ratio | 0.106 | ▲0.729 | ▲12.613 |
| Operating Cash Flow Coverage Ratio | 0.059 | ▲0.417 | ▲0.803 |
| Capital Expenditure Coverage Ratio | 6.352 | ▲220.926 | ▲96.562 |
| Dividend Paid And Capex Coverage Ratio | 6.352 | ▲220.926 | ▲96.562 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -102.509 | ▼-74.947 | ▼-67.297 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $11.00B | $7.70B | $6.41B | $6.40B | $6.48B | |
| Enterprise value | $11.26B | $7.99B | $6.76B | $6.57B | $6.24B | |
| EV / Sales | 16.27x | 21.98x | 25.36x | 128.35x | 802.71x | |
| EV / Op. cash flow | 217.41x | -26.11x | -14.47x | -13.25x | -14.95x | |
| EV / Free cash flow | 258.03x | -25.98x | -14.40x | -12.87x | -14.13x | |
| EV / EBITDA | -102.51x | -27.56x | -16.45x | -12.41x | -17.12x | |
| Net debt / EBITDA | -2.33x | -1.02x | -0.85x | -0.33x | 0.65x | |
| Current ratio | 1.04x | 1.17x | 0.95x | 1.29x | 8.03x | |
| Income quality | -0.24x | 0.81x | 0.97x | 0.85x | 1.09x | |
| Graham net-net | -$10 | -$8 | -$8 | -$0 | $9 | |
| Tax burden | 107.2% | 101.3% | 101.5% | 100.9% | 99.9% | |
| Interest burden | 161.1% | 121.3% | 110.2% | 105.6% | 101.0% | |
| Working capital | $39.6M | $153.0M | -$33.8M | $206.7M | $705.5M | |
| Invested capital | $189.7M | $255.7M | $81.3M | $340.6M | $836.9M | |
| Return on assets | -16.8% | -32.1% | -58.3% | -53.5% | -35.4% | |
| Operating ROA | -10.5% | -27.8% | -47.6% | -51.7% | -43.8% | |
| Return on tangible assets | -16.9% | -32.2% | -58.6% | -53.8% | -35.5% | |
| Return on equity | 134.6% | 357.7% | 330.4% | -221.5% | -43.4% | |
| Return on invested capital | -18.2% | -36.5% | -86.8% | -70.3% | -45.2% | |
| Return on capital employed | -56.2% | -102.6% | -511.4% | -150.6% | -45.9% | |
| Earnings yield | -2.0% | -4.9% | -7.5% | -9.1% | -5.9% | |
| Free cash flow yield | 0.4% | -4.0% | -7.3% | -8.0% | -6.8% | |
| Capex / Op. cash flow | 15.7% | -0.5% | -0.5% | -2.9% | -5.8% | |
| Capex / Depreciation | 47.9% | 8.1% | 12.9% | 80.7% | 157.5% | |
| Capex / Sales | 1.2% | 0.4% | 0.9% | 28.3% | 311.6% | |
| SG&A / Sales | 63.0% | 78.2% | 97.0% | 421.8% | 2059.4% | |
| R&D / Sales | 41.0% | 84.4% | 155.0% | 741.8% | 3803.9% | |
| Stock comp / Sales | 0.0% | 26.3% | 25.0% | 125.4% | 859.2% | |
| Intangibles / Total assets | 0.3% | 0.3% | 0.5% | 0.4% | 0.5% | |
| Days sales outstanding | 83d | 167d | 49d | 85d | 103d | |
| Days payables outstanding | 321d | 795d | 777d | 3038d | 6156d | |
| Operating cycle | 1149d | 2605d | 1767d | 4015d | 7916d | |
| Cash conversion cycle | 829d | 1810d | 989d | 976d | 1760d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-07 Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026 COPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual congress of the European Society for Paediatric Endocrinology (ESPE) being held September 8-10, 2026, in Marseille, France. Updates will include a podium presentation of the first sentinel cohort data from the pivotal reACHin Trial of TransCon CNP (navepegritide) in infants with achondroplasia aged 0 to
- 2026-08-31 Ascendis Pharma, Science Applications International And Other Big Stocks Moving Higher On Monday U.S. stocks were lower, with the Dow Jones index falling around 400 points on Monday.
- 2026-08-31 Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes On Sunday, BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reached a binding settlement with Ascendis Pharma A/S (NASDAQ:ASND)to resolve all global patent disputes regarding the medication Yuviwel.
- 2026-08-31 Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide) COPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin Pharmaceutical Inc. (“BioMarin”) related to the sale of YUVIWEL® and navepegritide-related products. The binding term sheet provides the terms and conditions upon which the companies agree to resolve all litigation and disputes between the companies.
- 2026-08-27 This Ascendis Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
- 2026-08-25 Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026 COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The presentation will be given by Carlos Bacino, M.D., FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children''s Hospital.
- 2026-08-18 Eyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration Patients First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injection
- 2026-08-13 Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript
- 2026-08-13 Ascendis Pharma A/S Q2 Earnings Call Highlights Ascendis Pharma A/S NASDAQ: ASND reported second-quarter 2026 total revenue of EUR 339 million, including EUR 315 million in product revenue, as demand for its three commercial TransCon-based therapies continued to increase.
- 2026-08-13 Ascendis Pharma Reports Second Quarter 2026 Financial Results – Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH ® , €55 million for SKYTROFA ® , and €8 million for YUVIWEL ®